Hussain Yaseen, Dormocara Amos, Li Huifang, Li Chengguo, Khan Muhammad Kamran, Ma Yonghao, Leng Gang, Wang Yipeng, You Ben-Gang, Cui Jing-Hao
College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Youwe (ZhuHai) Biotechnology Company Ltd, Zhuhai 519085, China.
Mol Pharm. 2025 Jul 7;22(7):4101-4124. doi: 10.1021/acs.molpharmaceut.5c00367. Epub 2025 May 27.
Deep skin fungal infections, particularly biofilm-associated (), pose significant clinical challenges due to their resistance to conventional antifungal therapies. The stratum corneum acts as a barrier to high molecular weight drugs, limiting the penetration of systemic and topical antifungal agents. In this study, we explored a transdermal delivery system utilizing novel Cathelicidin─HcCATH-KL30 (CATH)-loaded dissolving microneedles (DMNs) for the treatment of deep dermal biofilm infections. Preliminary evaluations demonstrated that CATH exhibited potent antifungal activity against nonfilamentous and filamentous but was ineffective against biofilm-embedded Candida, suggesting biofilm penetration limitations. To enhance its efficacy, we integrated indocyanine green into DMNs and applied photodynamic therapy (PDT) using near-infrared (NIR) irradiation. The generated reactive oxygen species disrupted the biofilm matrix, allowing a deeper penetration of CATH for enhanced antifungal activity. Results from in vitro, ex vivo, and in vivo models demonstrated a significant reduction (∼94%) in fungal burden with CATH-ICG-DMNs following NIR irradiation, highlighting a synergistic effect. Findings of the study were mechanistically validated through qRT-PCR and propodeum iodide staining, which were in accordance with the proposed hypothesis. The current research work for the first time explored the novel antimicrobial peptide from a drug delivery platform in order to investigate its potential. This study establishes a promising microneedle-based PDT strategy for combating deep skin fungal infections, overcoming biofilm-mediated resistance and enhancing antifungal therapy efficacy.
深部皮肤真菌感染,尤其是生物膜相关的感染,由于其对传统抗真菌疗法具有抗性,因而带来了重大的临床挑战。角质层对高分子量药物起到屏障作用,限制了全身和局部抗真菌药物的渗透。在本研究中,我们探索了一种经皮给药系统,该系统利用负载新型抗菌肽HcCATH-KL30(CATH)的溶解微针(DMN)来治疗深部真皮生物膜感染。初步评估表明,CATH对非丝状和丝状真菌均表现出强大的抗真菌活性,但对嵌入生物膜的念珠菌无效,这表明存在生物膜渗透限制。为提高其疗效,我们将吲哚菁绿整合到DMN中,并使用近红外(NIR)照射进行光动力疗法(PDT)。产生的活性氧破坏了生物膜基质,使CATH能够更深入地渗透,从而增强抗真菌活性。体外、离体和体内模型的结果表明,近红外照射后,CATH-ICG-DMN可使真菌负荷显著降低(约94%),突出了协同效应。该研究结果通过qRT-PCR和碘化丙啶染色进行了机制验证,这与提出的假设一致。当前的研究工作首次从药物递送平台探索了这种新型抗菌肽,以研究其潜力。本研究建立了一种有前景的基于微针的光动力疗法策略,用于对抗深部皮肤真菌感染,克服生物膜介导的抗性并提高抗真菌治疗效果。